Kura Oncology (KURA) Cash & Equivalents (2010 - 2026)
Kura Oncology (KURA) reported Cash & Equivalents of $39.1 million for Q1 2026, down 23.77% year-over-year from $51.3 million in Q1 2025, and down 73.79% on a QoQ basis from $149.1 million in Q4 2025.
Kura Oncology (KURA) has 17 years of Cash & Equivalents data on file, last reported at $39.1 million in Q1 2026.
- Quarterly Cash & Equivalents fell 23.77% year-over-year to $39.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.1 million (down 23.77% YoY) and the FY2025 annual result came in at $149.1 million, down 33.57% from the prior year.
- Cash & Equivalents slipped to $39.1 million in Q1 2026 per KURA's latest filing, from $149.1 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $224.5 million in Q4 2024 and bottomed at $27.1 million in Q1 2023.
- The 5-year median for Cash & Equivalents is $49.1 million (2023), against an average of $66.8 million.
- The widest annual swing landed in 2022, when Cash & Equivalents plunged 69.48%; it then surged 501.48% in 2024.
- Tracing KURA's Cash & Equivalents over 5 years: stood at $51.8 million in 2022, then dropped by 27.96% to $37.3 million in 2023, then surged by 501.48% to $224.5 million in 2024, then sank by 33.57% to $149.1 million in 2025, then slumped by 73.79% to $39.1 million in 2026.
- Per Business Quant, the three latest KURA Cash & Equivalents figures stand at $39.1 million (Q1 2026), $149.1 million (Q4 2025), and $95.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | 39.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.08 Mn |
| Dec 31, 2025 | 149.10 Mn |
| Sep 30, 2025 | 95.29 Mn |
| Jun 30, 2025 | 81.95 Mn |
| Mar 31, 2025 | 51.27 Mn |
| Dec 31, 2024 | 224.46 Mn |
| Sep 30, 2024 | 49.48 Mn |
| Jun 30, 2024 | 45.18 Mn |
| Mar 31, 2024 | 41.51 Mn |
| Dec 31, 2023 | 37.32 Mn |
| Sep 30, 2023 | 28.74 Mn |
| Jun 30, 2023 | 49.12 Mn |
| Mar 31, 2023 | 27.06 Mn |
| Dec 31, 2022 | 51.80 Mn |
| Sep 30, 2022 | 90.94 Mn |
| Jun 30, 2022 | 39.26 Mn |
| Mar 31, 2022 | 33.83 Mn |
| Dec 31, 2021 | 90.67 Mn |
| Sep 30, 2021 | 39.18 Mn |
| Jun 30, 2021 | 38.97 Mn |
| Mar 31, 2021 | 110.84 Mn |
| Dec 31, 2020 | 325.49 Mn |
| Sep 30, 2020 | 76.96 Mn |
| Jun 30, 2020 | 134.76 Mn |
| Mar 31, 2020 | 33.81 Mn |
| Dec 31, 2019 | 26.14 Mn |
| Sep 30, 2019 | 54.74 Mn |
| Jun 30, 2019 | 122.08 Mn |
| Mar 31, 2019 | 17.78 Mn |
| Dec 31, 2018 | 16.12 Mn |
| Sep 30, 2018 | 20.57 Mn |
| Jun 30, 2018 | 17.66 Mn |
| Mar 31, 2018 | 26.52 Mn |
| Dec 31, 2017 | 11.43 Mn |
| Sep 30, 2017 | 23.34 Mn |
| Jun 30, 2017 | 12.15 Mn |
| Mar 31, 2017 | 10.64 Mn |
| Dec 31, 2016 | 9.73 Mn |
| Sep 30, 2016 | 6.78 Mn |
| Jun 30, 2016 | 12.11 Mn |
| Mar 31, 2016 | 12.11 Mn |
| Dec 31, 2015 | 15.44 Mn |
| Sep 30, 2015 | 11.22 Mn |
| Jun 30, 2015 | 19.79 Mn |
| Mar 31, 2015 | 53.57 Mn |
| Dec 31, 2014 | 1.12 Mn |
| Sep 30, 2014 | 82,000.00 |
| Jun 30, 2014 | 4,918.00 |
| Mar 31, 2014 | 6,168.00 |
| Dec 31, 2013 | 6,568.00 |
| Sep 30, 2013 | 10,580.00 |
| Jun 30, 2013 | 18,705.00 |
| Mar 31, 2013 | 2,901.00 |
| Dec 31, 2012 | 4,802.00 |
| Sep 30, 2012 | 5,586.00 |
| Jun 30, 2012 | 9,481.00 |
| Mar 31, 2012 | 23,743.00 |
| Dec 31, 2011 | 4,220.00 |
| Sep 30, 2011 | 6,155.00 |
| Jun 30, 2011 | 9,255.00 |
| Mar 31, 2011 | 4,220.00 |
| Dec 31, 2010 | 26,898.00 |
| Sep 30, 2010 | 2,254.00 |